MedTrace Logo

A Study for PMS of AZL-M in the Treatment of Adult Participants With Essential Hypertension in South Korea

NCT04470817 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3438

Last updated 2023-10-26

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety by determining the incidence rates of all adverse events (AEs) including serious adverse events (SAEs)/serious adverse drug reactions (ADRs), unexpected AEs and ADRs that are not reflected on the precaution in the use, ADRs already known, non-serious ADRs and other safety related information (laboratory values changes, etc).

Conditions

  • Essential Hypertension

Interventions

DRUG

Azilsartan Medoxomil

Azilsartan Medoxomil

Sponsors & Collaborators

  • Celltrion Pharm, Inc.

    lead INDUSTRY

Principal Investigators

  • Medical Director · Celltrion Pharm, Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-07
Primary Completion
2023-05-25
Completion
2023-05-25

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04470817 on ClinicalTrials.gov